(Q46615368)

23 December 2017

title

Azotemia associated with use of lenalidomide in plasma cell dyscrasias (English)

1 reference

23 December 2017

1 reference

Vaishali Sanchorawala

series ordinal

2

1 reference

23 December 2017

Hillard M. Lazarus

series ordinal

4

object named as

Hillard M Lazarus

1 reference

23 December 2017

Eric D Batts

1

1 reference

23 December 2017

Yael Hegerfeldt

series ordinal

3

1 reference

23 December 2017

publication date

1 June 2008

1 reference

23 December 2017

published in

Leukemia & Lymphoma

1 reference

23 December 2017

volume

49

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

1108-1115

1 reference

23 December 2017

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802023707

10.1080/10428190802023707

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017